Wellbeing Subsidiary Mindscape Treats its 1,000th Patient

November 29, 2022
News

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its subsidiary Mindscape Ketamine & Infusion Therapy, PLLC (“Mindscape” or the “Clinic”), has treated its 1,000th patient with IV Ketamine Therapy for treatment-resistant mood disorders, mental health disorders and chronic pain conditions.

Ketamine is an anesthetic that has been used for over 50 years and is now being investigated across the nation as an off-label treatment of psychiatric disorders and pain conditions. Today, Mindscape aims to help facilitate patient healing using low-dose IV ketamine treatments. The Clinic reached the patient milestone in less than two years since its acquisition by Wellbeing, demonstrating the great need for this breakthrough treatment.

"In addition to the Clinic’s remarkable efficiency and reduction in treatment times, the clinical advantages of IV Ketamine therapy have also become increasingly evident,” said Najla Guthrie, CEO of Wellbeing Digital Sciences. “Ketamine has taken on a new life and is used more often to treat mood disorders, major depressive disorder, chronic pain, and other conditions that can make a person feel helpless or lost. We believe ketamine infusion therapy is the future of treating depression and can be a new light to a person whom other treatment options have failed.”

“Reaching this milestone is a testament to our mission to provide customized ketamine therapy while being mindful of the cost, and emotional, mental, and physical needs of our patients,” added Dr. Michael Ho, Medical Director of Mindscape Ketamine. “Through this innovative way of treating mental health and pain conditions, we continue to help patients reap the benefits of ketamine therapy and lead happier flourishing lives.”

ABOUT MINDSCAPE KETAMINE & INFUSION THERAPY

Subsidiary of Wellbeing Digital Sciences, Mindscape Ketamine & Infusions Therapy, PLLC is a clinic in Houston, Texas, offering affordable delivery of concierge IV ketamine therapy for treatment-resistant mood disorders, mental health disorders, and chronic pain conditions. Operated by Dr. Quang Henderson, a licensed Board-Certified Emergency Physician with over 20 years of experience with ketamine, Mindscape assists people dealing with depression, anxiety, PTSD, chronic pain, and other mood disorders using the medical procedure of IV ketamine treatments in low dose, high dose, or private sessions.

Mindscape is the only IV ketamine clinic in Houston to offer virtual reality-based guided meditation to complement IV ketamine infusions in the treatment of depression, bipolar disorder, anxiety, PTSD, OCD, and other mood disorders. For additional information, please visit mindscapeketamine.com.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.

On behalf of:
Najla Guthrie
Chief Executive Officer

WELLBEING DIGITAL SCIENCES

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.